Form 4: uniQure Director Sells Shares After Option Exercise

uniQure N.V. Director Robert Gut exercised stock options and subsequently sold a portion of his ordinary shares under a pre-arranged 10b5-1 plan.

Summary

• Director Robert Gut exercised options to acquire 17,810 ordinary shares of uniQure N.V. at an exercise price of $14.08 per share.
• Following the option exercise, Gut sold a total of 25,613 ordinary shares (17,310 + 500 + 7,803) in multiple transactions.
• The sales occurred at weighted average prices of $24.39, $25.03, and $25.09 per share.
• These transactions were executed on January 12, 2026, under a Rule 10b5-1 sales plan adopted on July 8, 2025.
• After these transactions, Gut beneficially owns 32,342 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns about new negative information. The director also realized a profit, which is positive for the individual but neutral for the company's immediate outlook.

Positives

• The director realized a significant profit by exercising options at $14.08 and selling shares at prices ranging from $24.02 to $25.09.
• The transactions were conducted under a pre-arranged 10b5-1 plan, indicating a planned sale rather than an immediate reaction to new information.

Negatives

• A director selling a substantial number of shares (25,613) could be perceived negatively by some investors, even if pre-planned.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This is an insider transaction report for a director of uniQure N.V., a biotechnology company. The transaction itself does not directly reflect broader industry trends but is a routine disclosure of executive stock activity within the sector.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on new, undisclosed information.

Key Dates

Recommendation

The filing details a pre-planned insider transaction where a director exercised options and sold shares. This is a routine event under a 10b5-1 plan and does not provide new fundamental information about the company's operations or future prospects. While the sale itself might be seen as a slight negative, the pre-planned nature suggests it's not based on new, undisclosed adverse information. Therefore, the filing alone does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

uniQure N.V., QURE, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transactions, 10b5-1 Plan, Biotechnology, Pharmaceuticals